


## ML 190

<b>Cat. No.:</b>	HY-107749
<b>CAS No.:</b>	1355244-02-8
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>32</sub> N <sub>6</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	488.58
<b>Target:</b>	Opioid Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	ML 190 is a selective $\kappa$ opioid receptor (KOR) antagonist with an IC <sub>50</sub> of 120 nM and an EC <sub>50</sub> of 129 nM, respectively <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 120 nM (KOR) <sup>[1]</sup> EC <sub>50</sub> : 129 nM (KOR) <sup>[1]</sup>
<b>In Vitro</b>	ML 190 exhibits plasma protein binding of 93.96% (1 $\mu$ M), 88.54% (10 $\mu$ M) in human and 88.46% (1 $\mu$ M), 80.07% (10 $\mu$ M) in mouse, respectively; plasma remaining percents of 100% at 3 hours in both human and mouse; hepatic microsome remaining percents of 22.13% and 7.34% at 1 hour in human and mouse, respectively; and hepatic toxicity LC <sub>50</sub> over 50 $\mu$ M [1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Frankowski KJ, et al. Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. ACS Chem Neurosci. 2012;3(3):221-236.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA